Business Wire

Bioptimus Appoints Mathilda Strom as Founding Chief Operating Officer

Share

Bioptimus, a leading AI company building the Foundation Model for biology, is thrilled to announce the appointment of Mathilda Strom as its Founding Chief Operating Officer. Mathilda joins Bioptimus with an extensive track record in building pioneering businesses and a reputation as a leader in scaling impactful organizations globally.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241114805370/en/

Mathilda Strom joins Bioptimus as Founding Chief Operating Officer (Photo: Business Wire)

With nearly 20 years of experience, Mathilda brings an entrepreneurial spirit and strategic vision to Bioptimus. Most recently, she served as the Chief Commercial Officer at CarbonPool, the world’s first insurance company to settle claims in carbon credits rather than cash.

Mathilda is no stranger to launching transformative companies. She co-founded BIMA, a microinsurance and digital health player in emerging markets. Under her leadership, BIMA expanded to 23 countries, enabling millions of low- and middle-income families to access critical financial and health services via mobile technology. Throughout her tenure, she forged deep-rooted partnerships with major global players, including Telefonica, Orange, Vodafone, Allianz, and Prudential, further cementing her reputation as an influential leader in the industry.

Beyond her executive experience, Mathilda has served on the boards of organizations like the Microinsurance Network and Azuri Technologies, a renewable energy firm working to bring solar solutions to Africa. She has earned recognition as one of the top 50 female entrepreneurs to watch and among the top 10 future women leaders in Sweden.

As Bioptimus’s new Chief Operating Officer, Mathilda Strom will oversee strategic operations, enhance organizational growth, and drive the company’s mission to fuel breakthroughs in biomedicine and beyond. Her proven expertise in building high-impact, purpose-driven ventures positions her to lead Bioptimus through its next phase of innovation and expansion.

David Cahané, Co-Founder of Bioptimus, said: ""We are thrilled to welcome Mathilda to Bioptimus as our Founding Chief Operating Officer. Her visionary leadership and track record in scaling impactful businesses align perfectly with our mission to fuel breakthrough discoveries and accelerate innovations in biomedicine and beyond. Mathilda’s expertise and commitment to innovation will be invaluable as we build the Foundation Model for biology to unlock the potential of generative AI in the field. We are excited to have her on board to help shape the future of our company.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20241114805370/en/

null

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Global Cell and Gene Therapy Trials: Driving Innovation in Oncology and Beyond14.11.2024 14:05:00 CET | Press release

Novotech, the global full-service clinical Contract Research Organization (CRO), has published its latest whitepaper, offering in-depth analysis and emerging trends and advancements within the rapidly evolving field of cell and gene therapies. The report provides critical insights into the growth of clinical trials, innovations and strategic opportunities, shaping the future of this field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241114441933/en/ Key Highlights from the Report:Global Clinical Trial Expansion: Over 1,500 drug candidates in development across phases 0 to III. CAR-T therapies account for 32% of the pipeline, primarily targeting hematological cancers. The global trial landscape experienced a 32.5% growth from 2019 to 2023, with Asia-Pacific leading in trial activity (44% of all trials). Oncology Focus: CAR-T and CAR-NK therapies represent ~30% of all cell and gene trials, with a strong focus on solid and h

REPLY: the Board of Directors Approves the Quarterly Financial Report as of 30 September 202414.11.2024 13:52:00 CET | Press release

All economic indicators have substantially improved:Consolidated turnover of €1,666.9 million (1,548.0 as at 30 September 2023)EBITDA of €275.5 million (235.8 as at 30 September 2023)EBIT of €224.2 million (187.7 as at 30 September 2023)Pre-tax profit of €216.0 million (170.3 as at 30 September 2023)Positive Net Financial Position of €312.6 million. Today, the Board of Directors of Reply [EXM, STAR: REY] approved the results as at 30 September 2024. The Group's consolidated turnover in the first nine months of the year reached €1,666.9 million, an increase of 7.7% compared to €1,548.0 million recorded on 30 September 2023. The indicators for the period are positive. Consolidated EBITDA was €275.5 million, equal to 16.5% of the consolidated revenues. As of September 2023 EBITDA was €235.8 million. EBIT, from January to September, reached €224.2 million, equal to 13.4% of the consolidated revenues. The corresponding 2003 figure was €187.7 million. Pre-tax profit, from January to Septembe

Experian Named to World’s Best Workplaces™ 2024 by Fortune and Great Place to Work®14.11.2024 13:22:00 CET | Press release

Recognition honours top 25 companies building the best workplace cultures in the world Experian today announced it was named one of the World’s Best Workplaces™ 2024 by Fortune and Great Place to Work®, which recognises a select 25 global companies that are building the best workplace cultures in the world. The honour highlights Experian’s people-first workplace culture that promotes inclusivity, fosters collaboration and innovation, and prioritises team member well-being, personal growth, and advancement. In its 14th year of producing this prestigious international list, Great Place To Work® surveyed 6.2 million employees worldwide on key factors that create great workplaces and analysed company workplace programmes that impact 18 million employees globally. Organisations were assessed on their efforts to create great workplaces and positively impact people and communities across multiple countries around the world. “This is a great recognition,” said Brian Cassin, Chief Executive Off

Rogers Investment Advisors leads FSR Angel 1 LPS investment in XELA Robotics Expansion to Drive Global Ambitions14.11.2024 13:00:00 CET | Press release

XELA Robotics Co., Ltd., (“XELA”), a pioneer in tactile sensing and advanced tactile AI-driven robotic solutions, today announced a significant 7-digit (USD) investment by FSR Angel 1 LPS (“FSR”), managed by Rogers Investment Advisors K.K.(“RIA”). The investment reinforces XELA’s vision to expand its global footprint while maintaining its position as a leader in tactile AI technology. The founding team will remain the majority shareholders of XELA, a company spun off from Waseda University, one of Japan’s most prestigious academic institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241114649471/en/ XELA Robotics CEO Alexander Schmitz with key investors from FSR Angel 1 LPS and Rogers Investment Advisors K.K., marking a pivotal step in our mission to expand globally and lead in AI-driven tactile sensing. (Graphic: Business Wire) XELA’s disruptive AI technology integrates tactile sensors to open new horizons for indus

BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer14.11.2024 12:00:00 CET | Press release

New name reflects Company’s bold vision to eradicate cancer by harnessing the transformative power of global collaboration and multisectoral partnershipsCompany will change its Nasdaq ticker to ONC BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced its intent to change the Company’s name to BeOne Medicines Ltd., confirming its commitment to develop innovative medicines to eliminate cancer by partnering with the global community to serve as many patients as possible. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241114671168/en/ (Graphic: Business Wire) “Cancer, a leading cause of death worldwide, exacts an immense toll on individuals, families, and communities. No person, family, scientist, clinician, hospital, policy maker, company or country can or should face this devastating disease alone. We all must work together to win, which is why we are committed to playing a critica

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye